142 related articles for article (PubMed ID: 31148369)
21. Asporin Interacts With HER2 to Promote Thyroid Cancer Metastasis
Zhan S; Wang T; Li J; Zhu H; Ge W; Li J
Front Oncol; 2022; 12():762180. PubMed ID: 35600399
[TBL] [Abstract][Full Text] [Related]
22. Notch1 receptor as a marker of lymph node metastases in papillary thyroid cancer.
Park HS; Jung CK; Lee SH; Chae BJ; Lim DJ; Park WC; Song BJ; Kim JS; Jung SS; Bae JS
Cancer Sci; 2012 Feb; 103(2):305-9. PubMed ID: 22118425
[TBL] [Abstract][Full Text] [Related]
23. REGγ Is Associated with Lymph Node Metastasis and T-Stage in Papillary Thyroid Carcinoma.
Qi L; He W
Med Sci Monit; 2018 Mar; 24():1373-1378. PubMed ID: 29509725
[TBL] [Abstract][Full Text] [Related]
24. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer.
Zhao H; Huang T; Li H
Surgery; 2019 Jul; 166(1):55-60. PubMed ID: 30876667
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
27. Predictive Value of BRAF
Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
[TBL] [Abstract][Full Text] [Related]
28. High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer.
Wang YY; Ye ZY; Zhao ZS; Tao HQ; Chu YQ
Ann Surg Oncol; 2010 Jan; 17(1):89-97. PubMed ID: 19820999
[TBL] [Abstract][Full Text] [Related]
29. Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer.
Lin P; Guo YN; Shi L; Li XJ; Yang H; He Y; Li Q; Dang YW; Wei KL; Chen G
Aging (Albany NY); 2019 Jan; 11(2):480-500. PubMed ID: 30661062
[TBL] [Abstract][Full Text] [Related]
30. In search of new stratification strategies: tissue proteomic profiling of papillary thyroid microcarcinoma in patients with localized disease and lateral neck metastases.
Matovinovic F; Novak R; Hrkac S; Salai G; Mocibob M; Pranjic M; Košec A; Bedekovic V; Grgurevic L
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17405-17417. PubMed ID: 37861757
[TBL] [Abstract][Full Text] [Related]
31. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
Gao WL; Wie LL; Chao YG; Wie L; Song TL
Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
[TBL] [Abstract][Full Text] [Related]
32. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
33. The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Fanaei SA; Hedayati M; Azizi F
BMC Cancer; 2018 Dec; 18(1):1199. PubMed ID: 30509240
[TBL] [Abstract][Full Text] [Related]
34. Identification of potential diagnostic and prognostic biomarkers for papillary thyroid microcarcinoma (PTMC) based on TMT-labeled LC-MS/MS and machine learning.
Li J; Mi L; Ran B; Sui C; Zhou L; Li F; Dionigi G; Sun H; Liang N
J Endocrinol Invest; 2023 Jun; 46(6):1131-1143. PubMed ID: 36418670
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of long noncoding RNA MALAT1 in papillary thyroid cancer and its diagnostic value.
Liu J; Dong H; Yang Y; Qian Y; Liu J; Li Z; Guan H; Chen Z; Li C; Zhang K; Zhang Q; Cao W; Lv J
Future Oncol; 2018 Dec; 14(29):3015-3022. PubMed ID: 29987950
[TBL] [Abstract][Full Text] [Related]
36. Autocrine activation of platelet-derived growth factor receptor α in metastatic papillary thyroid cancer.
Adewuyi EE; Deschenes J; Lopez-Campistrous A; Kattar MM; Ghosh S; McMullen TPW
Hum Pathol; 2018 May; 75():146-153. PubMed ID: 29408504
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
[TBL] [Abstract][Full Text] [Related]
39. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
[TBL] [Abstract][Full Text] [Related]
40. Relationships of BRAF mutation and HMGB1 to papillary thyroid carcinoma.
Guan X; Wang P; Chi J; Zhao S; Wang F
Biochem Biophys Res Commun; 2017 May; 486(4):898-903. PubMed ID: 28342873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
